ClinicalTrials.gg
RecruitingNCT07732244Updated Jul 28, 2026

Evaluating a Wireless NIRS Device in the Neonatal Intensive Care Unit

An interventional study of Wireless NIRS in Hypoxic-Ischemic Encephalopathy, Congenital Heart Disease and Stroke Hemorrhagic, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Nov 2025, registered May 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Hypoxia-Ischemia, Brain with a site in Canada — 10 open to participants now, 10 under way, none of them phase 3. Hypoxia-Ischemia, Brain · Canada.

Planned enrollment
12th of 14
20 · median 42
Started
2025
with 3 others
No phase
8 of 19
5 open now
Registered
18th of 19
by date
Lead sponsor
4 of 19
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 with no phase, and was the 18th registered.

Hypoxia-Ischemia, Brain

261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.

Browse Hypoxia-Ischemia, Brain studies →

Open to participants now

10 of the 19 studies in Hypoxia-Ischemia, Brain with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hypoxia-Ischemia, Brain with a site in Canada, or all of them as a file.
02

Study summary

The wireless NIRS sensor will be placed on the participant's forehead, directly underneath the INVOS wired sensor. The wireless NIRS sensor will remain in place for 4 consecutive hours, over 2 consecutive days. As standard-of-care, nursing personnel removes all sensors at every care to evaluate skin and reduce the risk of pressure sores. The wireless NIRS device will be removed and reapplied at the same time, by the research team who will annotate what time the sensor was removed, replaced, and the condition of the skin. This will be used to correlate signal disconnection with sensor care (i.e., skin checks, sensor removal, etc.).

03

Conditions studied

  • Hypoxic-Ischemic Encephalopathy
  • Congenital Heart Disease
  • Stroke Hemorrhagic
  • Aneurysm Cerebral

Keywords

  • NIRS
  • Near-Infrared Spectroscopy
  • Wireless Sensor
  • Technology
  • NICU
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants admitted to the NICU with a gestational age of ≥ 32 weeks at the time of the monitoring
  • undergoing monitoring with the INVOS wired NIRS system.

Exclusion criteria

Exclusion Criteria:

  • Infants with a skin abnormality that would potentially increase the risk of injury,
  • Patient too unstable or family experiencing too much stress as determined by an attending physician or bedside care team to not be approached for recruitment.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Wireless Near-infrared spectroscopy (NIRS)

    Wireless NIRS applied to participant's forehead.

    Device: Wireless NIRS

Interventions

  • DeviceWireless NIRS

    Wireless NIRS applied to participant forehead.

06

What researchers measure

Primary outcomes

  1. Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.

    Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.

    Time frame: 6 months

Secondary outcomes

  1. Comparison of SpO2 and Heart Rate (HR) data between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    Comparison of SpO2 and Heart Rate (HR) data between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    Time frame: 6 months

  2. Comparison of derived Heart Rate Variability (HRV) between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    Comparison of derived Heart Rate Variability (HRV) between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    Time frame: 6 months

  3. Provide a questionnaire to capture the perspectives of clinicians and patients' parents/guardians regarding use of the wireless NIRS compared to wired NIRS device.

    Provide a a custom study questionnaire to capture the perspectives of clinicians and patients' parents/guardians regarding use of the wireless NIRS compared to wired NIRS device. The questionnaire includes Likert-scale items, multiple-choice questions, and open-ended responses evaluating usability, perceived safety, accuracy, comfort, and acceptability. Responses will be summarized descriptively by questionnaire item.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 8 months after the start.

Of 46 non-industry interventional studies with no phase under Hypoxia-Ischemia, Brain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 47 studies reached it within 33 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
Jul 28, 2026
StartActual
Nov 15, 2025
Primary completionEst.
Aug 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732244
Responsible party
Guilherme Sant'Anna, MD (Neonatologist, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jul 28, 2026
Start date
Nov 15, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Alyssa Maximov, BSc
Contact
alyssa.maximov@muhc.mcgill.ca
5149341934 ext. 78229
Guilherme Sant'Anna, MD, PhD
principal investigator · RI-MUHC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion